Mineralys Therapeutics has reported positive results from the Target-HTN Phase II clinical trial of lorundrostat to treat uncontrolled and resistant hypertension.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,